EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ELISA Development for Serum Hemeoxygenase-1 and Its Application to Patients with Acute Respiratory Distress Syndrome

Yu Hara iD, Masaharu Shinkai iD, Masataka Taguri, Kenjiro Nagai, Satoru Hashimoto, Takeshi Kaneko

Canadian Respiratory Journal · 2018 · 2018 · 1-7

DOI: 10.1155/2018/9627420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Respiratory Journal, 2018. Verfasst von Yu Hara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hemeoxygenase-1 (HO-1) is an essential enzyme in heme catabolism and has been proposed as a biomarker of lung disease prognosis. We modified a commercial HO-1 enzyme-linked immunosorbent assay (ELISA) kit to achieve higher sensitivity and evaluated if serum HO-1 could be a biomarker to predict the prognosis of acute respiratory distress syndrome (ARDS) patients.

Methods

Serum samples were collected from 15 healthy volunteers to validate the modified ELISA. In the 22 patients with ARDS who were enrolled, serum HO-1 was measured upon diagnosis (D0) and at 7 days after diagnosis (D7).

Results

The serum HO-1 concentration could be measured in all healthy volunteers. The intra- and interassay tests and the percentage recovery test were acceptable. Compared with normal control subjects, patients with ARDS had significantly higher D0 HO-1 concentrations (75.4 ng/mL versus 31.7 ng/mL, P < 0.001 ). The 28-day survival was significantly better in patients with low D0 HO-1 (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultAgedCase-Control StudiesEnzyme-Linked Immunosorbent AssayFemaleHeme Oxygenase-1HumansMaleMiddle AgedPrognosisRespiratory Distress SyndromeSensitivity and SpecificitySurvival Rate

Substanzen

HMOX1 protein, humanHeme Oxygenase-1

Autor:innen und Institutionen

  • Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.
  • Division of Intensive Care Unit, Kyoto Prefectural University of Medicine, Kyoto, Japan.

ORCID-Profile: Yu Hara, Masaharu Shinkai

Zitieren

APA

Hara, Y., Shinkai, M., Taguri, M., Nagai, K., Hashimoto, S., & Kaneko, T. (2018). ELISA Development for Serum Hemeoxygenase-1 and Its Application to Patients with Acute Respiratory Distress Syndrome. Canadian Respiratory Journal, 2018, 1-7. https://doi.org/10.1155/2018/9627420

Vancouver

Hara Y, Shinkai M, Taguri M, Nagai K, Hashimoto S, Kaneko T. ELISA Development for Serum Hemeoxygenase-1 and Its Application to Patients with Acute Respiratory Distress Syndrome. Canadian Respiratory Journal. 2018;2018:1-7. doi:10.1155/2018/9627420

BibTeX
@article{Hara2018,
  author = {Hara, Yu and Shinkai, Masaharu and Taguri, Masataka and Nagai, Kenjiro and Hashimoto, Satoru and Kaneko, Takeshi},
  title = {ELISA Development for Serum Hemeoxygenase-1 and Its Application to Patients with Acute Respiratory Distress Syndrome},
  journal = {Canadian Respiratory Journal},
  year = {2018},
  volume = {2018},
  pages = {1--7},
  doi = {10.1155/2018/9627420}
}
Kostenlos starten →